Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
ELEV Stock Forecast 2025-2026
$0.37
Current Price
$21.63M
Market Cap
Buy 0
Hold 5
Sell 0
Wall St Analyst Ratings
Distance to ELEV Price Targets
+37.0%
To High Target of $0.50
-1.4%
To Median Target of $0.36
-1.4%
To Low Target of $0.36
ELEV Price Momentum
0.0%
1 Week Change
0.0%
1 Month Change
-38.3%
1 Year Change
-33.9%
Year-to-Date Change
-86.4%
From 52W High of $2.68
+65.2%
From 52W Low of $0.22
📊 TOP ANALYST CALLS
Did ELEV Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Elevation Oncology is one of their latest high-conviction picks.
Latest ELEV Stock Price Targets & Analyst Predictions
Based on our analysis of 10 Wall Street analysts, ELEV has a neutral consensus with a median price target of $0.36 (ranging from $0.36 to $0.50). The overall analyst rating is Buy (6.0/10). Currently trading at $0.37, the median forecast implies a -1.4% downside. This outlook is supported by 0 Buy, 5 Hold, and 0 Sell ratings.
Conversely, the most conservative target is provided by Swayampakula Ramakanth at HC Wainwright & Co., suggesting a 1.4% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ELEV Analyst Ratings
0
Buy
5
Hold
0
Sell
ELEV Price Target Range
Low
$0.36
Average
$0.36
High
$0.50
Current: $0.37
Latest ELEV Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ELEV.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jun 10, 2025 | HC Wainwright & Co. | Swayampakula Ramakanth | Neutral | Downgrade | $0.36 |
| Jun 10, 2025 | JMP Securities | Silvan Tuerkcan | Market Perform | Reiterates | $N/A |
| Jun 9, 2025 | William Blair | Andy Hsieh | Market Perform | Downgrade | $N/A |
| Mar 24, 2025 | Stephens & Co. | Sudan Loganathan | Equal-Weight | Downgrade | $1.00 |
| Mar 21, 2025 | JMP Securities | Market Perform | Reiterates | $N/A | |
| Mar 21, 2025 | Citizens Capital Markets | Silvan Tuerkcan | Market Perform | Downgrade | $7.00 |
| Mar 21, 2025 | Piper Sandler | Biren Amin | Neutral | Downgrade | $0.70 |
| Mar 21, 2025 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Maintains | $1.00 |
| Mar 21, 2025 | Leerink Partners | Andrew Berens | Market Perform | Downgrade | $1.00 |
| Mar 10, 2025 | Citizens Capital Markets | Silvan Tuerkcan | Market Outperform | Reiterates | $7.00 |
| Mar 10, 2025 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Reiterates | $6.00 |
| Mar 7, 2025 | Stephens & Co. | Sudan Loganathan | Overweight | Reiterates | $5.00 |
| Jan 14, 2025 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Reiterates | $6.00 |
| Jan 3, 2025 | William Blair | Outperform | Initiates | $N/A | |
| Dec 19, 2024 | JMP Securities | Market Outperform | Reiterates | $N/A | |
| Dec 13, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Dec 6, 2024 | Stephens & Co. | Sudan Loganathan | Overweight | Reiterates | $5.00 |
| Aug 7, 2024 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Reiterates | $6.00 |
| Jul 15, 2024 | JMP Securities | Silvan Tuerkcan | Market Outperform | Reiterates | $7.00 |
| Jun 28, 2024 | JMP Securities | Silvan Tuerkcan | Market Outperform | Reiterates | $7.00 |
Elevation Oncology Inc. (ELEV) Competitors
The following stocks are similar to Elevation Oncology based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
ELEV
Elevation Oncology
mkt cap
21.63M
Elevation Oncology Inc. (ELEV) Financial Data
Elevation Oncology Inc. has a market capitalization of $21.63M with a P/E ratio of -0.5x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -78.3%.
Valuation Metrics
Market Cap
$21.63M
Enterprise Value
$-27,789,338
P/E Ratio
-0.5x
PEG Ratio
-0.1x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+373.2%
Current Ratio
19.4x
Debt/Equity
66.9x
ROE
-78.3%
ROA
-29.9%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Elevation Oncology Inc. (ELEV) Business Model
About Elevation Oncology Inc.
What They Do
Develops targeted therapies for cancer treatment.
Business Model
Elevation Oncology focuses on researching and developing precision medicine targeted at specific genetic alterations in cancer. The company generates revenue through partnerships, collaborations with pharmaceutical companies, and potentially through the commercialization of its proprietary therapies once they receive regulatory approval.
Additional Information
As a player in the burgeoning field of personalized medicine, Elevation Oncology is positioned to address unmet medical needs in cancer treatment, which could lead to significant advancements in patient care and potential profitability as the demand for targeted therapies continues to grow.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
34
CEO
Ms. Tammy Furlong CPA, P.M.P.
Country
United States
IPO Year
2020
Website
elevationoncology.comElevation Oncology Inc. (ELEV) Latest News & Analysis
Latest News
Quick Summary
Monteverde & Associates is investigating Elevation Oncology's sale to Concentra Biosciences, offering $0.36 per share and contingent rights for shareholders.
Why It Matters
The investigation into Elevation Oncology's sale raises concerns about potential shareholder value. Uncertainty around the deal's fairness could impact stock performance and investor confidence.
Source: GlobeNewsWire
Market Sentiment:
Neutral
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates KNW, ELEV, CRKN on Behalf of Shareholders
5 months ago
Quick Summary
Halper Sadeh LLC is investigating Know Labs, Inc. (NYSE: KNW) for potential federal securities law violations related to its sale to Goldeneye 1995 LLC. Shareholders can explore their legal options.
Why It Matters
Investigations into Know Labs' sale may indicate potential legal issues or breaches of fiduciary duty, impacting shareholder value and investor confidence in the company.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Elevation Oncology has agreed to a merger with Concentra Biosciences for $0.36 per share plus a contingent value right, approved unanimously by its Board.
Why It Matters
The merger signals a potential exit strategy for Elevation Oncology investors, offering immediate cash and contingent value rights, which may enhance total return based on future asset performance.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Halper Sadeh LLC is investigating the fairness of Elevation Oncology's sale to Concentra Biosciences, offering shareholders $0.36 per share plus contingent value rights.
Why It Matters
Concerns about the fairness of Elevation Oncology's acquisition may signal potential undervaluation, impacting share prices and investor confidence in the deal's outcome.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Elevation Oncology is set to be sold to Concentra Biosciences for $0.36 per share plus a contingent value right for net cash, as investigated by Kahn Swick & Foti, LLC.
Why It Matters
The investigation into Elevation Oncology's sale may signal potential risks or disputes affecting the deal, impacting shareholder value and market perception.
Source: Business Wire
Market Sentiment:
Neutral
Elevation Oncology Reports First Quarter 2025 Financial Results and Provides Business Updates
6 months ago
Quick Summary
Elevation Oncology presented preclinical data for HER3 ADC EO-1022 at the AACR Annual Meeting and plans to file an IND application in 2026, with cash runway extending into 2H 2026.
Why It Matters
The preclinical data for EO-1022 suggests a promising new cancer therapy, potentially boosting Elevation Oncology's market position and attracting investor interest as they approach key regulatory milestones.
Source: PRNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About ELEV Stock
What is Elevation Oncology Inc.'s (ELEV) stock forecast for 2026?
Based on our analysis of 10 Wall Street analysts, Elevation Oncology Inc. (ELEV) has a median price target of $0.36. The highest price target is $0.50 and the lowest is $0.36.
Is ELEV stock a good investment in 2026?
According to current analyst ratings, ELEV has 0 Buy ratings, 5 Hold ratings, and 0 Sell ratings. The stock is currently trading at $0.37. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for ELEV stock?
Wall Street analysts predict ELEV stock could reach $0.36 in the next 12 months. This represents a -1.4% decrease from the current price of $0.37. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Elevation Oncology Inc.'s business model?
Elevation Oncology focuses on researching and developing precision medicine targeted at specific genetic alterations in cancer. The company generates revenue through partnerships, collaborations with pharmaceutical companies, and potentially through the commercialization of its proprietary therapies once they receive regulatory approval.
What is the highest forecasted price for ELEV Elevation Oncology Inc.?
The highest price target for ELEV is $0.50 from at , which represents a 37.0% increase from the current price of $0.37.
What is the lowest forecasted price for ELEV Elevation Oncology Inc.?
The lowest price target for ELEV is $0.36 from Swayampakula Ramakanth at HC Wainwright & Co., which represents a -1.4% decrease from the current price of $0.37.
What is the overall ELEV consensus from analysts for Elevation Oncology Inc.?
The overall analyst consensus for ELEV is neutral. Out of 10 Wall Street analysts, 0 rate it as Buy, 5 as Hold, and 0 as Sell, with a median price target of $0.36.
How accurate are ELEV stock price projections?
Stock price projections, including those for Elevation Oncology Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: December 4, 2025 5:34 AM UTC